Hydroxychloroquine *Versus* COVID-19: A Periodic Systematic Review and Meta-Analysis

Amir Shamshirian^{1,2}, Amirhossein Hessami^{3,4}, Keyvan Heydari^{2,3}, Reza Alizadeh-Navaei^{2*}, Mohammad Ali Ebrahimzadeh⁴, George W. YIP⁶, Roya Ghasemian⁷, Morteza Behnamfar⁸, Hananeh Baradaran⁹, Elham Aboufazeli¹⁰, Hamed Jafarpour³, Keyvan Karimifar¹¹, Aida Eftekhari¹¹, Danial Shamshirian^{12*}

1. Department of Medical Laboratory Sciences, Student Research Committee, School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari, Iran.

2. Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.

3. Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

4. Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

5. Pharmaceutical Sciences Research Center, Department of Medicinal Chemistry, School of Pharmacy, Mazandaran University of Medical Science, Sari, Iran.

6. Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

7. Antimicrobial Resistance Research Center, Department of Infectious Diseases, Mazandaran University of Medical Sciences, Sari, Iran.

8. Student Research Committee, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.

9. Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

10. Department of Research and Development, IRAN NAJO Pharmaceutical Company, Tehran, Iran.

11. Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

12. Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Tel: +98 912 640 6146

E-Mail: reza_nava@yahoo.com Tel: +98 911 114 7563

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Corresponding authors:

^{1.} Danial Shamshirian, Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-Mail: shamshirian@sbmu.ac.ir

^{2.} Reza Alizadeh-Navaei; Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.

Hydroxychloroquine *Versus* COVID-19: A Periodic Systematic Review and Meta-Analysis

Key Points

Question: Is hydroxychloroquine effective and safe against COVID-19?!

Findings: This systematic review and meta-analysis on 18 studies including 5,561 participants indicated no significant clinical effectiveness for hydroxychloroquine with/without azithromycin against COVID-19 patients. Also, the higher mortality rate and adverse effects were observed in the HCQ/HCQ+AZM regimen group.

Meaning: It seems that hydroxychloroquine does not works as expected and attracted attentions as a potential agent against COVID-19, so, we should be cautious about the treatment decision.

Abstract

Importance: This systematic review and meta-analysis not only indicated no clinical benefits regarding hydroxychloroquine (HCQ) treatment with/without azithromycin for COVID-19 patients, but the higher mortality rate and frequency of known HCQ adverse effects were observed for the HCQ/HCQ+AZM regimen group.

Objective: To overcome the controversies regarding the effectiveness of hydroxychloroquine in the treatment of COVID-19 through meta-analysis.

Data Sources: A systematic search was performed in PubMed, Scopus, Embase, Cochrane Library, Web of Science, Google Scholar and medRxiv pre-print database using all available MeSH terms for COVID-19 and hydroxychloroquine up to May 14, 2020.

Study Selection: Studies focused on the effectiveness of HCQ with/without azithromycin (AZM) in confirmed COVID-19 patients were entered into the study including: comparative or non-comparative clinical studies including observational/interventional studies with retrospective/prospective nature with/without control group as well as Randomized Clinical Trials (RCTs).

Data Extraction and Synthesis: Two researchers have independently evaluated quality assessment of the studies and abstracted data for data extraction, which has reviewed by the supervisor for accuracy. Extracted data were analyzed using CMA v. 2.2.064. Heterogeneity was assessed using the *I*-squared (I^2) test, and fixed/random-effects model was used when appropriate for pooling of studies.

Main Outcome(s) and Measure(s): 1) Clinical effectiveness of HCQ with/without AZM in the treatment of COVID-19; 2) Mortality rate; 3) Disease exacerbation; 4) Frequency of known HCQ adverse effects occurred during treatment; 5) Intubation need; 6) Radiological improvement.

Results: Out of 21 studies entered into our systematic review, 18 studies including 11 comparative studies with control group and seven observational studies containing 5,561 participants have entered into the study. The results of the meta-analysis on comparative studies indicated no significant clinical effectiveness (negative in RT-PCR evaluation) for HCQ regimen in the treatment of COVID-19 in comparison to control group (RR: 0.96, 95% CI, 0.76-1.22). The same result was observed for the combination of HCQ+azithromycin (RR: 2.15, 95% CI, 0.31-14.77). Approximately 1.5 times higher mortality rate was observed among the HCQ regimen group (RR: 1.54, 95% CI, 1.04-2.29) and 3.5 times higher in HCQ+AZM (RR: 3.65, 95% CI, 1.10-12.10) group in comparison to control group, which was affected by age differences according to meta-regression analysis (P=0.0003). No substantial difference was observed for disease exacerbation (RR: 1.60, 95% CI, 0.54-4.71) between HCQ group and controls. Also, radiological findings significantly improved in the HCQ group (OR: 0.32, 95% CI, 0.11-0.98). Odds of known HCO adverse effects (diarrhea, vomiting, blurred vision, rash, headache, etc.) occurred in the HCQ regimen group was approximately 3.5 times of control group (OR: 3.55, 95% CI, 1.61-7.82), but no substantial differences were found regarding intubation odds between HCQ group and control group (OR: 2.11, 95% CI, 0.31-14.03).

Conclusions and Relevance: This systematic review and meta-analysis not only showed no clinical benefits regarding HCQ treatment with/without azithromycin for COVID-19 patients, but according to multiple sensitivity analysis, the higher mortality rates were observed for both HCQ and HCQ+AZM regimen groups, especially in the latter. Also, frequency of adverse effects was higher in HCQ regimen group. However, due to that most of the studies were non-randomized and results were not homogenous, selection bias was unavoidable and further large randomized clinical trials following comprehensive meta-analysis should be taken into account in order to achieve more reliable findings.

Keywords: Pandemic, 2019-nCoV, Coronavirus Outbreaks, SARS-CoV-2

Introduction:

A novel coronavirus emerged from Wuhan, China, in December 2019 has named respiratory syndrome coronavirus 2 (SARS-CoV-2) and declared as a pandemic by World Health Organization (WHO) on March 26, 2020¹. According to Worldometer metrics, this novel virus has been responsible for approximately 4,507,689 infections and 302,315 death worldwide up to May 14, 2020.

Although a few months have passed since the onset of the new challenging disease, there is still no specific preventive and therapeutic approach in this regard. Therefore, the quarantine approach, personal hygiene, and social distancing are the basic protective measures against Coronavirus Disease 2019 (COVID-19) according to WHO advice for the public ².

Moreover, according to a large amount of ongoing research regarding this pandemic issue, many controversies are arising daily among different fields of sciences, which has confronted a "*pandemic*" with an "*infodemic*" (e.g. *Is coronavirus an airborne? Is COVID-19 transmitted vertically in pregnancy? Should everyone wear a mask? How long can the virus survive on surfaces? Is it possible to get COVID-19 for a second time?* etc.).

In this regard, one of the hottest controversies is the hydroxychloroquine (HCQ) efficacy with/without azithromycin (AZM) for COVID-19 patients. While, several studies are talking about promising effects of HCQ regimen against SARS-CoV-2 infection for both prevention and treatment ³⁻⁵, others try to come up with neutral or even harmful effects of this drug for such patients when there is no ample evidence ⁶. It is unavoidable that all these controversies affect the patient's outcome significantly.

Although there are some systematic reviews and meta-analysis in this regard ^{7,8}, they suffer from several limitations and flaws that should be addressed with a more comprehensive study. Hence, due to the importance of the subject we carried out a rapid systematic review and meta-analysis, which will be updated periodically to report stronger evidence, which might help to overcome the controversies about the effectiveness of HCQ against COVID-19.

Method:

Study design & information

The current study has designed by The Tabari Systematic Review Group (TSRG) with an updating approach named "Periodic Systematic Review and Meta-analysis", which will be updated time to time whenever a new substantial study is published. Also, different versions will be released in newly under design of this study our platform at https://rtp.mazums.ac.ir/Page/9/Tabari-Systematic-Review-Group.

Search Strategy

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was followed for study design, search protocol, screening, and reporting. A systematic search was performed *via* databases of PubMed, Scopus, Embase, Cochrane Library, Web of Science and Google Scholar (intitle) as well as preprint database of medRxiv up to May 6, 2020. Moreover, gray literature and references of eligible papers were considered for more available data in this case. The search strategy included all MeSH terms and free keywords found for COVID-19, SARS-CoV-2, and hydroxychloroquine. There was no time/location/language limitation in this search.

Criteria study selection

Two researchers (A.H and K.H) have screened and selected the papers independently and discussed to solve the disagreements with the third-party (R.A/D.Sh). Studies met the following criteria included into meta-analysis: 1) comparative or non-comparative clinical studies including observational/interventional studies with retrospective/prospective nature with/without control group as well as Randomized Clinical Trials (RCTs); and 2) studies reported the effect of HCQ with/without AZM in confirmed COVID-19 patients. Studies were excluded if they were: 1) animal studies, reviews, case reports, and *in vitro* studies; 2) duplicate publications; and 3) insufficient for calculating of desired parameters.

Data extraction & quality assessment

Two researchers (A.Sh and A.H) have independently evaluated quality assessment of the studies and extracted data from selected papers. The supervisors (D.Sh/MA.E) resolved any disagreements in this step. Data extraction checklist included the name of the first author, publication year, region of study, number of patients, number of controls, mean age, treatment option, medication dosage, treatment duration, adverse effects, radiological results, nasopharyngeal culture status through Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and mortality.

The Jadad scale, ROBINS-*I* tool and Newcastle-Ottawa Scale (NOS) checklists were used to value the selected randomized controlled trials, non-randomized controlled trials and observational studies, respectively concerning various aspects of the methodology and study process. Risk-of-bias plots have been created through the *robvis* online tool ⁹.

Targeted outcomes

1) Clinical effectiveness of HCQ with/without AZM in the treatment of COVID-19; 2) Mortality rate; 3) Disease exacerbation; 4) Frequency of known HCQ adverse effects occurred during treatment; 5) Intubation need; 6) Radiological improvement.

Comparisons

1) HCQ in comparison to control group with standard treatment; 2) HCQ+AZM in comparison to control group with standard treatment.

Definitions

- **Clinical effectiveness:** nasopharyngeal swab culture resulted negative in RT-PCR evaluation.
- **Disease exacerbation:** clinical symptoms of the disease are worsened.
- Adverse effects: occurrence of known symptoms related to HCQ such as diarrhea, vomiting, blurred vision, rash, headache, etc.
- **Group-A** in forest plots: the case groups who receive HCQ with/without AZM regimen.
- **Group-B** in forest plots: the control groups without HCQ/HCQ+AZM regimen.

Heterogeneity assessment

I-square (I^2) statistic was used for heterogeneity evaluation. Following Cochrane Handbook for Systematic Reviews of Interventions ¹⁰, the I^2 was interpreted as follows: "0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity. The importance of the observed value of I^2 depends on (i) magnitude and direction of effects and (ii) strength of evidence for heterogeneity (e.g. P-value from the chi-squared test, or a confidence interval for I^2)."

In case of heterogeneity, DerSimonian and Laird random-effects model was applied to pool the outcomes; otherwise, the inverse variance fixed-effect model was used. Forest plots were presented to visualize the degree of variation between studies.

Data analysis

Statistical analysis was performed using Comprehensive Meta-Analysis (CMA) v. 2.2.064 software. Risk Ratio (RR) or Odds Ratio (OR) were used for outcome estimation whenever appropriate with 95% Confident Interval (CI). Fixed/random-effects model was used according to heterogeneities. In case of zero frequency, the correction value of 0.1 was used. Meta-regression analysis was done to examine the impact of age difference on HCQ regimen group mortality RR. However, due to insufficient data we could not apply the meta-regression analysis on the other moderator variables such as sex, underlying disease, etc.

Publication bias & sensitivity analysis

Begg's and Egger's tests as well as funnel plot was used for publication bias evaluation. *P*-value less than 0.05 was considered as statistically significant.

According to that the sensitivity analysis known as an essential part in systematic reviews with meta-analysis to determine the robustness of the obtained outcomes to the assumptions made in the data analysis ¹¹, we conducted a sensitivity analysis to examine the effect of studies that greatly influence the result, especially by their weight through excluding them from the meta-analysis.

Results

Study selection process

The databases search resulted in 352 papers. Eighty-nine duplicated papers have been excluded and after first step screening, fifteen papers were assessed for eligibility. Finally, 21 papers entered into qualitative synthesis, of which 18 papers entered into the meta-analysis. PRISMA flow diagram for the study selection process presented in Figure 1.




Figure 1.PRISMA flow diagram for the study selection process

Study characteristics

Out of 18 studies entered into the meta-analysis, 11 studies were comparative randomized and non-randomized (only two studies were randomized) and seven were observational, of which, HCQ arms of the comparative studies has been combined with observational studies for effect size meta-analysis. The studies' sample size ranged from 10 to 1438 including 5,561 participants. Characteristics of studies entered into the systematic review presented in Table 1.

Table 1. Characteristics of studies entered into the systematic review

Study	Country	Quality Score/ Risk of Bias	Patients type	No. Patients	Cases	Controls	Treatment regimen	Duration (days)	Mean age (± SD)
Chen et al. 2020 ¹²	China	5/8*	Nonsevere	62	31	31	HCQ 400 mg/d	5	44.7 (± 15.3)
Jun et al. 2020 ¹³	China	5/8*	-	30	15	15	HCQ 400 mg/d	5	-
Mahévas et al. 2020 ¹⁴	France	5/8*	Nonsevere	181	84	97	HCQ 600 mg/d	7	-
Tang et al. 2020 ¹⁵	China	6/8*	Mild, Moderate, Severe	150	70	80	HCQ 400-800 mg/d	14-21	46.1 (±14.7)
Gautret (A) et al. 2020 ¹⁶	France	8/9**	-	80	80	-	HCQ 400 mg/d + AZM	10	52.1 (± 14.8)
Gautret (B) et al. 2020 17	France	Moderate***	-	36	14	16	HCQ 600 mg/d	6	45.1 (± 22)
Guulet (B) er ul. 2020	Thinee	moderate	-	50	6	16	HCQ 600 mg/d + AZM #	0	10.1 (± 22)
Magagnoli et al. 2020 ¹⁸	USA	8/9**	-	368	97	158	HCQ		
Magagnon et al. 2020	USA	0/9***	-	308	113	158	HCQ+AZM	-	-
Molina <i>et al.</i> 2020 ¹⁹	France	Moderate***	Severe	11	11	-	HCQ 600 mg/d + AZM	6	58.7 (± 14.3)
Chorin et al. 2020 ²⁰	USA	8/9**	-	84	84	-	HCQ + AZM	-	63 (± 15)
Joshua et al. 2020 ²¹	USA	Moderate***	-	63	32	31	HCQ 200-400 mg/d	5	62.7 (± 15)
Million et al. 2020 ²²	France	6/9**	-	1061	1061	-	HCQ + AZM	3<	43.6
Bo Yu <i>et al.</i> 2020 ²³	China	6/9**	Critically ill	568	48	520	HCQ 400 mg/d	7-10	67 (± 14.0)
Membrillo et al. 2020 ²⁴	Spain	6/9**	Mild, Moderate, Severe	166	123	43	HCQ ‡	-	-
Mallat <i>et al.</i> 2020 ²⁵	UAE	7/9**	Mild, Moderate	34	23	11	HCQ §	10	38.6 (± 12.5)
Lee et al. 2020 ²⁶	South Korea	7/9**	Mild, Moderate	72	27	-	HCQ 400 mg/d	-	38 (± 22.9)
Barbosa et al. 2020 ²⁷	Brazil	Moderate***	-	636	412	224	HCQ + AZM ¶	6	62.5 (± 15.5)
Carlucci et al. 2020	USA	7/9**	-	521	521	-	HCQ Ł	5	61.83 (± 15.97)
December of al 2020 ²⁸	USA	8/9**		1438	735	-	HCQ + AZM	$\leq 1\text{-}2 \leq$	-
Rosenberge et al. 2020 ²⁸	USA	8/9***	-	1458	271	-	HCQ	\leq 0-1 \leq	-
Saleh et al. 2020 29	USA	7/9**	-	201	201	-	$HCQ + AZM \Psi$	4-5	58.5 (± 9.1)
Geleris et al. 2020 ³⁰	USA	7/9**	Moderate, Severe	1376	811	565	HCQ + AZM \not	\leq 4 \leq	-
2					10	-	HCQ		
Ramireddy et al. 2020 ³¹	USA	-	-	98	61	-	HCQ + AZM	-	62.3 (± 17)

HCQ: hydroxychloroquine, AZM: azithromycin,

USA: United States of America, UAE: United Arab Emirates

*Quality assessed using Jadad Checklist

** Quality assessed using the Newcastle-Ottawa Scale Checklist

*** Risk of Bias assessed using ROBINS I tool

500mg on day1 followed by 250mg per day, the next four days

¶Hydroxychloroquine 800mg on the first day and 400mg for another 6 days and azithromycin 500mg once daily for five days.

*†*The suggested HCQ regimen was a loading dose of 600 mg twice on day 1, followed by 400 mg daily for 4 additional days. Azithromycin at a dose of 500 mg on day 1 and then 250 mg daily for 4 more days in combination with HCQ was an additional suggested therapeutic option. *‡*Initial loading dose of 800mg

 $Q 400 \ {\rm mg}$ was administered twice daily for 1 day, followed by 400 mg daily for 10 days. $L 400 \ {\rm mg}$ load followed by 200 mg twice daily for five days

Quality assessment

Results of quality assessment for studies entered into meta-analysis using Jadad, ROBINS-*I* and NOS checklists were reported in Table 1 and summary of risk of bias has presented in Fig. 2.




Figure 2. Summary of risk of bias for studies entered into meta-analysis

Publication bias

Results of Begg's and Egger's tests for every performed analysis were insignificant as follows: hydroxychloroquine regimen effectiveness ($P_B=0.42$; $P_E=0.55$), association between hydroxychloroquine regimen and mortality rate in controlled randomized and non-randomized studies ($P_B=1.00$; $P_E=0.81$) and overall mortality in all studies ($P_B=0.09$; $P_E=0.01$). The funnel plot for publication bias of studies presented in Supplementary Fig. 1.

Meta-analysis findings

Treatment outcome

Hydroxychloroquine regimen effectiveness

The meta-analysis of risk ratios (RR) for HCQ effectiveness in all of the comparative randomized and non-randomized studies showed that there were no significant differences between case group, who received the standard treatment with HCQ regimen and the control group that received the standard treatment without HCQ (RR: 0.96, 95% CI, 0.76-1.22). We also found no significant risk difference (RD) between two groups regarding effectiveness of HCQ in COVID-19 patients (RD: 0.00, 95% CI, -0.18-0.18) (Fig. 3). Also, no substantial effectiveness for HCQ was found by meta-analysis of only controlled randomized studies as well (RR: 1.19, 95% CI, 0.87-1.63; RD: 0.12, 95% CI, -0.07-0.33) (Fig. 4).

tudy name		Sta	tistics for e	ach study			Even	ts / Total			Risk ratio and	95% CI			
	Risk ratio	Lower limit	Upper limit	Z-Valu	ie p	-Value	Group-A	Group-B							Relative weight
Z. Chen	1.471	1.023	2.114	2.08	32	0.037	25/31	17/31	1	1	H	F I	1		16.03
P. Gautret (B)	4.571	1.158	18.053	2.16	39	0.030	8/14	2/16			-				2.59
C. Jun	0.929	0.730	1.181	-0.60	15	0.545	13/15	14/15							20.53
J. Magagnoli	0.814	0.711	0.933	-2.96	6	0.003	70/97	140/158			_				24.12
W. Tang	1.055	0.915	1.216	0.73	37	0.461	60/70	65/80							23.93
J. Mallat	0.526	0.330	0.838	-2.70	12	0.007	11/23	10/11			T				12.80
	0.968	0.767	1.221	-0.27		0.781					-+				
											•				
Heterogen	eity: I ² =	78.90%,	r² = 0.05,	p-value	= 0.00	, z-value	e = -0.27,	df = 5	0.01	0.1 Favours a	1 A	10 Favours B	100		
Heterogeno Risk Dif	eity: I ² =	78.90%,		p-value		, z-value	e = -0.27,	df = 5 Events / Tot			4		100		
Heterogeno Risk Dif	eity: I ² =	78.90%,		-		, z-value zValue	e = -0.27,	Events / Tot			4	Favours B	100		Relative weight
Random ef Heterogene Risk Dif	eity: I ² =	78.90%, 1	Statistics	for each study Lower	Upper			Events / Tot Group-A G			4	Favours B	100		Relative weight 16.14
Heterogen Risk Dif Study name 2. Chm 2. Chm 2. Chm 3. Gadret (B)	eity: ² = ference 0.256 0.446	78.90%, 1 CC Standard error 0.114 0.155	Statistics Variance 0.013 0.024	for each study Lower limit 0.034 0.141	Upper limit 0.482 0.752	ZValue 2.261 2.802	p-Value 0.024 0.034	Events / Tot Group-A G 25 / 31 8 / 14	al roup-B 7 / 31 2/ 16		4	Favours B	100		weight 16.14 13.42
Heterogens Risk Dif Stady name Z Oren P. Gadret (B) C. Jun	Risk difference 0.256 0.446 -0.067	78.90%, 1 CCE Standard error 0.114 0.155 0.100	Statistics Variance 0.013 0.024 0.012	for each study Lower limit 0.004 0.141 -0.280	Upper limit 0.482 0.752 0.147	ZValue 2.261 2.862 -0.612	p-Value 0.024 0.034 0.540	Events / Tot Group-A G 255/31 8/14 13/15	al roop-88 2/10 4/15		4	Favours B	100		weight 16.14 13.42 16.49
Heterogens Risk Dif Study name Z. Chen P. Gaulet (B) C. Jun J. Magagnali	Risk difference 0.256 0.466 -0.067 -0.164	78.90%, 1 Ce Standard error 0.114 0.155 0.100 0.052	Statistics Variance 0.013 0.024 0.012 0.003	for each study Lower limit 0.034 0.141 -0.280 -0.266	Upper limit 0.482 0.782 0.147 -0.082	2Value 2.281 2.802 -0.612 -3.159	p-Value 0.024 0.540 0.002	Events / Tot Group-A G 25 / 14 8 / 14 13 / 15 70 / 97 1-	al 7731 2713 4715 07158		4	Favours B	100		weight 16.14 13.42 16.49 19.81
Heterogens Risk Dif Bludy name 2 Chen P. Gaulest (B) C. Jun Magagnoli W Tang	Risk difference 0.256 0.446 -0.067 -0.164 0.045	78.90%, * CE Standard error 0.114 0.155 0.100 0.052 0.050	Statistics Variance 0.013 0.024 0.012 0.003 0.004	for each study Lower limit 0.034 0.141 -0.280 -0.266 -0.074	Upper limit 0.482 0.752 0.147 -0.062 0.163	2Value 2.261 2.662 -0.612 -3.159 0.739	p-Value 0.024 0.034 0.540 0.002 0.460	Events / Tot Group-A G 25 / 31 8 / 14 13 / 15 70 / 97 15 20 / 70	al 7731 2713 4715 6718 6780		4	Favours B	100		weight 16.14 13.42 16.49 19.81 19.40
Heterogens Risk Dif Bludy name 2 Chen P. Gaulest (B) C. Jun Magagnoli W Tang	Risk difference 0.256 0.440 -0.067 -0.164 0.045 -0.431	78.90%, * CCC Standard error 0.114 0.155 0.100 0.052 0.055 0.136	Statistics Variance 0.013 0.024 0.012 0.003 0.004 0.018	for each study Lower limit 0.034 0.141 -0.280 -0.074 -0.074 -0.895	Upper limit 0.482 0.752 0.147 4.062 0.163 4.0165	ZValue 2.261 2.602 3.159 0.739 -3.179	p-Value 0.024 0.034 0.540 0.002 0.460 0.001	Events / Tot Group-A G 25 / 31 8 / 14 13 / 15 70 / 97 15 20 / 70	al 7731 2713 4715 07158		4	Favours B	100		weight 16.14 13.42 16.49 19.81
Heterogens Risk Dif Study name Z. Chen P. Gaulet (B) C. Jun J. Magagnali	Risk difference 0.256 0.446 -0.067 -0.164 0.045	78.90%, * CE Standard error 0.114 0.155 0.100 0.052 0.050	Statistics Variance 0.013 0.024 0.012 0.003 0.004	for each study Lower limit 0.034 0.141 -0.280 -0.266 -0.074	Upper limit 0.482 0.752 0.147 -0.062 0.163	2Value 2.261 2.662 -0.612 -3.159 0.739	p-Value 0.024 0.034 0.540 0.002 0.460	Events / Tot Group-A G 25 / 31 8 / 14 13 / 15 70 / 97 15 20 / 70	at roup-8 7 / 31 2 / 10 0 / 158 6 / 80 0 / 11	Favours	Risk diff	Favours B			weight 16.14 13.42 16.49 19.81 19.40
Heterogene Risk Dif Study name Z. Chen P. Gaulos (B) C. Jun J. Magagnoli W. Tang J. Matat	Risk ference 0.256 0.406 -0.067 -0.164 0.067 -0.454 0.043 0.000	78.90%, * CE Standard error 0.114 0.155 0.100 0.052 0.055 0.135 0.025	Statistics Variance 0.013 0.024 0.012 0.003 0.004 0.018	for each study Lower limit 0.034 0.141 -0.280 -0.074 -0.074 -0.895	Upper limit 0.482 0.752 0.147 4.062 0.163 4.0165	ZValue 2.261 2.602 3.159 0.739 -3.179	p-Value 0.024 0.034 0.540 0.002 0.460 0.001	Events / Tot Group-A G 25 / 31 8 / 14 13 / 15 70 / 97 15 20 / 70	al 7731 2713 4715 6718 6780	Favours	4	Favours B	100	1.00	weight 16.14 13.42 16.49 19.81 19.40
Heterogens Risk Dif Bludy name 2 Chen P. Gaulest (B) C. Jun Magagnoli W Tang	Risk Risk difference 0.256 0.466 -0.067 -0.164 0.045 -0.431 0.000 ffect mode	78.90%, * CC Standard error 0.114 0.155 0.055 0.055 del	Statistics Variance 0.013 0.024 0.012 0.003 0.004 0.018 0.009	for each study Lower limit 0.1041 0.280 0.286 -0.074 4.0855 -0.103	Upper limit 0.482 0.752 0.147 -0.062 0.163 -0.169	Z-Value 2.261 -0.612 -3.159 -0.739 -3.179 -0.034	p-Value 0.024 0.540 0.002 0.460 0.002 0.007 0.007	Events / Tot Group-A G 25/31 8/14 13/15 70/97 15 70/97 11/23	at roup-8 7 / 31 2 / 10 0 / 158 6 / 80 0 / 11	Favours /	Risk diff	Favours B			weight 16.14 13.42 16.49 19.81 19.40

Group-A: Hydroxychioroquir Group-B: Control

Figure 3. Forest plot for pooling risk ratios and risk differences regarding hydroxychloroquine regimen in comparative randomized and non-randomized studies

tudy name		Stat	istics for ea	ch study			Events	s / Total			Risk ratio	and 95% CI			
	Risk ratio	Lower limit	Upper limit	Z-Value	e p-\	Value	Group-A	Group-B							Relative weight
Z. Chen	1.471	1.023	2.114	2.082	2 (0.037	25/31	17/31				-	1	- 1	36.84
N. Tang	1.055	0.915	1.216	0.737	7 (0.461	60/70	65/80			1				63.16
	1.192	0.871	1.632	1.098	в (0.272						•			
									0.01	0.1			10	100	
Random e	effect mod	lel													
Heterogen	neity: 2 =	64 13%													
		01.1070,1	- 0.00,	p-value -	= 0.09,	z-value	= 1.09, d	lf = 1		-					
Risk Dit			- 0.00,	p-value -	= 0.09,	z-value	= 1.09, d	lf = 1		Favou	s A	Fa	vours B		
				p=Vellue -		z-value	= 1.09, d	If = 1 Events/	Total	Favou		Fa k difference and			
				 b. Marinteners 		z-value	= 1.09, d		Total Group-8	Favour					Relative weight
Risk Dif Study name 7 Chen	fferenc	Standard	Statistics	s for each study Lower	Usper			Events/		Favour					
Study name 7. Chen	Risk difference 0.258 0.045	Standard error 0.114 0.000	Statistics Variance 0.013 0.004	s for each study Lower limit 0.034 -0.071	Upper limit 0.482 0.163	ZValue 2 261 0.739	p-Value 0.004 0.460	Events/ Group-A	Group-B	Favour					weight
Study name 7. Chen	fference Risk difference 0.258	Standard error 0 114	Statistics Variance 0.013	s for each study Lower limit 0034	Upper limit 0.482	ZValue 2.261	p-Value 0.024	Events/ Group-A 25/31	Group-B 17 / 31	Favou					weight 39.71
	Risk difference 0.258 0.045	Standard error 0.114 0.000	Statistics Variance 0.013 0.004	s for each study Lower limit 0.034 -0.071	Upper limit 0.482 0.163	ZValue 2 261 0.739	p-Value 0.004 0.460	Events/ Group-A 25/31	Group-B 17 / 31	Favour					weight 39.71
Study name 7 Chen	Fisk difference 0.258 0.045 0.129	Standard error 0.114 0.000 0.104	Statistics Variance 0.013 0.004	s for each study Lower limit 0.034 -0.071	Upper limit 0.482 0.163	ZValue 2 261 0.739	p-Value 0.004 0.460	Events/ Group-A 25/31	Group-B 17 / 31		R	k difference and	96%,CI		weight 39 71 60.29
Study name Z. Chen W. Tang	Risk difference 0.258 0.045 0.129	Standard error 0.114 0.000 0.104 del	Statistics Variance 0.013 0.004 0.011	s for each study Lower limit 0.034 -0.074 -0.075	Upper limit 0.452 0.163 0.334	Z-Value 2 261 0.739 1.239	p-Value 0.024 0.460 0.215	Events./ Group-A 25731 63770	Group-B 17 / 31		R	k difference and	96%,CI	в	weight 39 71 60.29
Study name 2 Chen W. Tang Random e	Risk difference 0.258 0.045 0.129	Standard error 0.114 0.000 0.104 del	Statistics Variance 0.013 0.004 0.011	s for each study Lower limit 0.034 -0.074 -0.075	Upper limit 0.452 0.163 0.334	Z-Value 2 261 0.739 1.239	p-Value 0.024 0.460 0.215	Events./ Group-A 25731 63770	Group-B 17 / 31		Pi -0.50	k difference and	96% CI	в	weight 39 71 60.29

Figure 4. Forest plot for pooling risk ratios and risk differences regarding hydroxychloroquine regimen in only controlled randomized studies

Sensitivity analysis for hydroxychloroquine regimen effectiveness

Regardless of separate analysis only on controlled randomized studies (Fig. 4), to evaluate the impact of inverse RRs as well as studies' weight on the meta-analysis results, we conducted several sensitivity analyses as follows: 1) according to the substantial relative weight of three studies on the meta-analysis, by excluding these studies as follows no significant changes was observed: Jun (B) *et al.* (RR: 0.98, 95% CI, 0.73-1.32), Magagnoli *et al.* (RR: 1.02, 95% CI, 0.75-1.39), and Tang *et al.* study (RR: 0.95, 95% CI, 0.69-1.32) (Supplementary Fig. 2-4); 2) Exclusion of above three studies was also resulted in no significant differences (RR: 1.28, 95% CI, 0.49-3.33) (Supplementary Fig. 5); 3) considering four studies with *P*-value less than 0.05; two have a *P*<0.05 in favour of Group-A and two has a *P*<0.05 in favour of Group-B; these are the Magagnoli *et al.* and Mallat *et al.* studies, for which the 95% CI of RR has no intersection with the Chen *et al.* and Gautret (B) *et al.*, thus, the new sensitivity analysis by excluding studies of Magagnoli *et al.* Mallat *et al.*, resulted in no difference as well (RR: 1.15, 95% CI, 0.88-1.49) (Supplementary Fig. 6); and 4) by excluding both studies in favour of Group-A, meta-analysis showed no significant difference similarly (RR: 0.86, 95% CI, 0.70-1.05) (Supplementary Fig. 7).

Hydroxychloroquine + azithromycin regimen

No significant difference was found for effectiveness of HCQ+AZM combination regimen in comparison to control group in comparative studies entered into meta-analysis (RR: 2.15, 95% CI, 0.31-14.77; RD: 0.37, 95% CI, -0.58-1.33) (Fig. 5).




Figure 5. Forest plot for pooling risk ratios and risk differences regarding hydroxychloroquine + azithromycin

regimen

Hydroxychloroquine regimen & mortality rate

The meta-analysis of death outcome in comparative randomized and non-randomized studies showed no significant differences for mortality rate between HCQ regimen group and standard treatment group (RR: 1.03, 95% CI, 0.50-2.09; RD: -0.02, 95% CI, -0.12-0.08) (Fig. 6).

study name		Sta	tistics for e	ach study		Ever	nts / Total		RISK F	atio and 95% CI			
	Risk ratio	Lower limit	Upper limit	Z-Value	p-Value	Group-A	Group-B						Relative weight
P. Gautret (B)	3.400	0.149	77.337	0.768	0.443	1/14	0/16	1	I —			-1	4.16
J. Magagnoli	2.443	1.424	4,193	3.241	0.001	27/97	18/158						19.24
J. Barbosa	2.471	0.244	24,982	0.766	0.444	2/17	1/21		· · · · ·				6.56
M. Mahevas	0.866	0.199	3,760	-0.192	0.848	3/84	4/97						11.24
B. Yu	0.410	0.226	0.744	-2.933	0.003	9/48	238/520		_				18.78
E. S. Rosenberg	1.573	1.033	2.395	2.111	0.035	54/271	28/221						20.12
F. J. Membrillo	0.449	0.286	0.707	-3.465	0.001	27 / 123	21/43						19.90
Wernbrind	1.031	0.507	2.095	0.084	0.933	277120	21/45		2.00				13.50
	1.031	0.507	2.095										
												1	
Random effec Heterogeneity Risk Diffe	/: l² = 83	.65%, t² :	= 0.60, p-		00, z-value	= 0.08, df	= 6	0.01	l 0.1 Favours A	1 Fa	l 10 vours B	I 100	
Heterogeneity Risk Diffe	/: l² = 83	.65%, t² :			00, z-value	= 0.08, df	= 6 Events / Tota				vours B	1 100	
Heterogeneity Risk Diffe ^{Study name}	/: l² = 83	.65%, t² :		value = 0. reach study Lower U	por z-value	= 0.08, df	Events / Tota			Fa	vours B	1 100	Relative weight
Heterogeneity Risk Diffe ^{Study name}	/: ² = 83 rence Risk	.65%, T ² : Standard	Statistics fo	value = 0. ^{yr} eachstudy Lower u limit	per	p-Value	Events / Tota Group-A Gr			Fa	vours B	I 100	
Heterogeneity Risk Diffe ^{Study name}	/: ² = 83 rence Risk fference	.65%, T ² =	Statistics fo Variance	value = 0. vreach study Lower U limit -0.100	oper mit Z-Value	p-Value 0.415	Events / Tota Group-A Ge 1 / 14 (1	L Dup-8		Fa	vours B	100	weight
Heterogeneity Risk Diffe Study name P. Gautret (B) J. Magagnoli J. Bartosa	7: ² = 83 rence 0.071 0.164 0.070	.65%, T ² = standard error 0.088 0.052 0.091	Statistics fo Variance 0.008 0.003 0.008	value = 0. vreach study Lower limit -0.100 0.062 -0.108	per mit Z-Value 0.243 0.810 0.266 3.155 0.248 0.770	p-Value 0.415 0.002 0.441	Events / Tota Group-A Ga 1 / 14 () 27 / 97 11 2 / 17 1	50 09-88 0/16 0/159 1/21		Fa	vours B	100	weight 12.20 15.28 11.92
Heterogeneity Risk Diffe Study name P. Gautret (B) J. Magagnoli J. Bartosa M. Matrowas	7: ² = 83 rence 0.071 0.164 0.070 -0.006	.65%, T ² = standard error 0.088 0.052 0.091 0.029	Statistics fo Variance 0.008 0.003 0.008 0.009	value = 0. vreach study Lower U limit -0.100 0.062 -0.108 -0.062	per mit Z-Value 0.243 0.810 3.166 3.160 1.248 0.777 1.051 -0.193	p-Value 0.415 0.002 0.441 0.847	Events / Tota Group-A Ga 1 / 14 (1 27 / 97 1 2 / 17 1 3 / 84 4	50 09-8 7 16 7 456 7 21 7 21 7 21 7 27		Fa	vours B	100	weight 12.20 15.28 11.92 16.91
Heterogeneity Risk Diffe Study name P. Gautret (B) J. Magagnoli J. Bartosa M. Mathrous B Yu	Risk fference 0.071 0.164 0.070 -0.008 -0.270	.65%, T ² = Standard error 0.088 0.052 0.091 0.029 0.060	Statistics fo 0.008 0.003 0.003 0.003 0.001 0.001	value = 0.	sper mit Z-Value 1.243 0.810 1.248 0.770 1.248 0.770 0.051 -0.193 1.152 -4.477	p-Value 0.415 0.002 0.441 0.847 0.000	Events / Tota Group-A Gr 1 / 14 (27 / 97 18 2 / 17 1 3 / 84 4 9 / 48 23	50 09-85 7 16 7 16 7 21 7 21 7 897 7 560		Fa	vours B	100	weight 12.20 15.28 11.92 16.91 14.59
Heterogeneity Risk Diffe Study name P. Guttrr (B) J. Magagnoli J. Mathwas B. Yu E. S. Rosenbarg	Risk Fence 0.071 0.164 0.070 -0.006 -0.270 0.073	Standard error 0.088 0.052 0.091 0.029 0.029 0.033	Statistics fo Variance 0.008 0.008 0.008 0.001 0.004 0.001	value = 0.	rper mit Z-Value 1.243 0.816 1.266 3.169 1.248 0.777 0.051 -0.130 1.051 -0.130 1.152 -4.477 1.137 2.159	p-Value 0.415 0.002 0.441 0.847 0.000 0.028	Events / Tota Group-A Gr 27/ 97 11 2/ 17 1 3 / 64 2 9 / 48 2 54 / 271 22	oup- B / 16 / 21 / 21 / 37 / 3600 / 221		Fa	vours B	I 100	weight 12.20 15.28 11.92 16.91 14.59 16.66
Heterogeneity Risk Diffe Study name P. Gautret (B) J. Magagnoli J. Bartosa M. Mathrous B. Yu	Risk fference 0.071 0.164 0.070 -0.008 -0.270	.65%, T ² = Standard error 0.088 0.052 0.091 0.029 0.060	Statistics fo 0.008 0.003 0.003 0.003 0.001 0.001	value = 0.	sper mit Z-Value 1.243 0.810 1.248 0.770 1.248 0.770 0.051 -0.193 1.152 -4.477	p-Value 0.415 0.002 0.441 0.847 0.000 0.028 0.002	Events / Tota Group-A Gr 27/ 97 11 2/ 17 1 3 / 64 2 9 / 48 2 54 / 271 22	50 09-85 7 16 7 16 7 21 7 21 7 897 7 560		Fa	vours B	I 100	weight 12.20 15.28 11.92 16.91 14.59
Heterogeneity Risk Diffe Study name P. Guttrr (B) J. Magagnoli J. Matwas B. Yu E. S. Rosenbarg	/: ² = 83 rence 0.071 0.164 0.070 -0.005 -0.020 -0.023 0.023 -0.289 -0.289	.65%, T ² = standard error 0.088 0.052 0.091 0.029 0.029 0.029 0.029 0.029 0.029 0.029 0.029 0.029 0.029	Statistics fo Variance 0.008 0.003 0.008 0.001 0.004 0.001 0.007	value = 0.	rper mit Z-Value 0.243 0.611 0.266 3.150 0.248 0.777 0.051 -0.192 1.152 -447 0.152 -447 0.152 -447 0.153 -3.166	p-Value 0.415 0.002 0.441 0.847 0.000 0.028 0.002	Events / Tota Group-A Gr 27/ 97 11 2/ 17 1 3 / 64 2 9 / 48 2 54 / 271 22	500-8 7 16 7 21 7 21 7 21 7 22 7 22 7 22 7 22 7 22	Favours A	Fa	vours B *** 		weight 12.20 15.28 11.92 16.91 14.59 16.66
Heterogeneity Risk Diffe Study name P. Gautrer (B) J. Magagnoli J. Bartosa M. Matrwas B. Yu E. S. Reserbarg F. J. Merritrillo	Risk ference 0.071 0.164 0.070 0.006 -0.200 -0.773 -0.209 -0.020	.65%, T ² = standard error 0.088 0.052 0.091 0.029 0.029 0.029 0.029 0.029 0.029 0.029 0.029 0.029 0.029	Statistics fo Variance 0.008 0.003 0.008 0.001 0.004 0.001 0.007	value = 0.	rper mit Z-Value 0.243 0.611 0.266 3.150 0.248 0.777 0.051 -0.192 1.152 -447 0.152 -447 0.152 -447 0.153 -3.166	p-Value 0.415 0.002 0.441 0.847 0.000 0.028 0.002	Events / Tota Group-A Gr 27/ 97 11 2/ 17 1 3 / 64 2 9 / 48 2 54 / 271 22	oup- B / 16 / 21 / 21 / 37 / 36 / 36 20 / 221	Favours A	Fa	vours B	I 100	weight 12.20 15.28 11.92 16.91 14.59 16.66
Heterogeneity Risk Diffe Study name P. Guttrr (B) J. Magagnoli J. Matwas B. Yu E. S. Rosenbarg	Risk Rest ference 0.071 0.104 0.070 -0.020 0.073 -0.229 -0.020 ct ct	,65%, 7 ² : Standard error 0.088 0.052 0.060 0.086 0.066	Statistics fo 0.008 0.008 0.009 0.001 0.001 0.007 0.003	value = 0.	oper Z-Value 0.243 0.810 0.266 3.166 0.249 0.767 0.51 -0.160 1.152 -4.47 1.163 -3.168 0.000 -0.366	p-Value 0.415 0.002 0.441 0.047 0.000 0.028 0.002 0.722	Events / Tota Group-A Gr 27/197 11 2/177 11 2/177 12 3/181 2 3/184 23 54/271 22 27/123 2	500-8 7 16 7 21 7 21 7 21 7 22 7 22 7 22 7 22 7 22	Favours A	Fa	vours B *** 		weight 12.20 15.28 11.92 16.91 14.59 16.66

Group-B : Control

Figure 6. Forest plot for pooling risk ratios and risk differences regarding mortality rate in randomized and non-randomized studies

Sensitivity analysis for hydroxychloroquine regimen mortality

Due to the surprising mortality rate in the control group of the Yu *et al.* and Membrillo *et al.* studies, which led to the inverse RR in comparison to other studies and high weight in final estimation in our analysis, we have conducted a sensitivity analysis by excluding these studies. The sensitivity analysis resulted in approximately two times higher mortality rate in HCQ regimen arm in comparison to control group (RR: 1.81, 95% CI, 1.31-2.49) (Supplementary Fig. 8). In addition, concerning significant influence of Magagnoli *et al.* study on mortality rate (P=0.001), we have performed another sensitivity analysis by excluding above three studies, which indicated about 1.5 higher mortality rate in the HCQ regimen group than the control group in randomized and non-randomized studies (RR: 1.54, 95% CI, 1.04-2.29) (Supplementary Fig. 9).

Meta-regression analysis on effects of age differences on mortality

Meta-regression findings indicated that age differences of studies had substantial effects on risk ratios related to the HCQ regimen group mortality rate (P=0.0003) (Fig. 7).




Figure 7. Meta-regression plot for effect of age difference on hydroxychloroquine regimen mortality Risk Ratio

Hydroxychloroquine + azithromycin regimen & mortality rate

The meta-analysis of mortality outcome in comparative randomized and non-randomized studies indicated approximately 3.5 times higher mortality rate in HCQ+AZM regimen group in comparison to control group (RR: 3.65, 95% CI, 1.10-12.10; RD: 0.40, 95% CI, -0.18-1.00) (Fig. 8).


Study name		Sta	tistics for e	ach study		Ever	nts / Total			Risk ra	tio and 95%	CI		
	Risk ratio	Lower limit	Upper limit	Z-Value	p-Value	Group-A	Group	р-В						Relative weight
J. Magagnoli	1.942	1.114	3.385	2.341	0.019	25/113	18/1	58	- f	1		- T	- 1	48.39
E. S. Rosenberg	6.601	4.647	9.375	10.540	0.000	189/226	28/2	21			_	.		51.61
	3.652	1.102	12.104	2.118	0.034									
									0.01	0.1	1	10	100	
Heterogeneity		2.48%, t²	= 0.69, p-	-value = 0.	00, z-value	= 2.11, df	= 1			Favours A		Favours B	100	
Heterogeneity Risk Diffe	y: l² = 92	2.48%, t²		value = 0.	00, z-value	= 2.11, df	= 1 Events	/ Total		Favours A	Risk difference ar	Favours B		
Heterogeneity Risk Diffe ^{Study name}	y: l² = 92	2.48%, t²		for each study Lower U	00, z-value	= 2.11, cf		/ Total Group-B		Favours A		Favours B		Relative weight
Heterogeneity Risk Diffe ^{Study name}	y: ² = 92	2.48%, τ ²	Statistics	for each study Lower U limit I	© xper		Events			Favours A		Favours B		
Heterogeneity Risk Diffe ^{Study name}	V: 2 = 92 PRENCE Risk (fference 0.107 0.710	2.48%, T ²	Statistics I Variance 0.002 0.001	for each study Lower U limit ! 0.016 0.614	oper imit Z:Value 0,190 2.300 0,775 21.333	p-Value 0.021 0.000	Events Group-A	Group-B		Favours A		Favours B	-	weight
Heterogeneity Risk Diffe Study name di J. Magagnoli	Y: ² = 92 Prence Risk ifference 0.107	2.48%, T ²	Statistics I Variance 0.032	for each study Lower U limit ! 0.016 0.614	oper imit ZValue 0.190 2.300	p-Value 0.021	Events Group-A 25 / 113	Group-B 187 158		Favours A		Favours B	-	weight 49.85
Heterogeneity Risk Diffe Study name di J. Magagnoli	V: 2 = 92 PRENCE Risk (fference 0.107 0.710	2.48%, T ²	Statistics I Variance 0.002 0.001	for each study Lower U limit ! 0.016 0.614	oper imit Z:Value 0,190 2.300 0,775 21.333	p-Value 0.021 0.000	Events Group-A 25 / 113	Group-B 187 158		Favours A		Favours B	-	weight 49.85
Heterogeneity Risk Diffe Study name di J. Magagnoli	Y: ² = 92 Prence 0.107 0.710 0.409	2.48%, T ²	Statistics I Variance 0.002 0.001	for each study Lower U limit ! 0.016 0.614	oper imit Z:Value 0,190 2.300 0,775 21.333	p-Value 0.021 0.000	Events Group-A 25 / 113	Group-B 187 158		Favours A	Risk difference ar	Favours B d 99% ci	-	weight 49.85 50.15

Group-B : Control

Figure 8. Forest plot for pooling risk ratios and risk differences regarding mortality rate in randomized and non-randomized studies

Overall mortality

For overall mortality we considered the treatment arms of the all comparative studies as observational studies and combined all types together as observational. Pooling mortality rate of studies resulted in overall mortality of 10% (95% CI, 6%-16%) for both HCQ and HCQ+AZM regimen (Fig. 9).



HCQ: Hydroxychloroquine AZM: Azithromycin

Figure 9. Forest plot for pooling mortality rates

Disease exacerbation


Meta-analysis of all comparative studies showed that the disease exacerbation was not significantly different between HCQ group and control group (RR: 1.60, 95% CI, 0.54-4.71; RD: 0.04, 95% CI, -0.05-0.14) (Fig. 10). Also, doing meta-analysis only on controlled randomized studies indicated no considerable disease exacerbation differences between two groups (RR: 0.59, 95% CI, 0.04-7.79; RD: -0.08, 95% CI, -0.32-0.14) (Fig. 11).

P. Gautret (B) 7.933 Barbosa 4.324 V. Tang 3.423 E. S. Rosenberg 1.571 1.608 1.808	Lower limit 0.052 0.445 1.029 0.142 1.022 0.548	Upper limit 0.946 141.425 18.166 82.689 2.414 4.719	2-Value -2.034 1.409 1.999 0.757 2.059 0.864	p-Value 0.042 0.159 0.046 0.449 0.039 0.387	Group-A 2/31 3/14 7/17 1/70 52/271	Group - 9/31 0/16 2/21		·	┼■╶	1.		J	Relative weight 22.50
P. Gautret (B) 7.933 J. Barbosa 4.324 W. Tang 3.423 E. S. Rosenberg 1.571 1.608 Random effect model	0.445 1.029 0.142 1.022	141.425 18.166 82.689 2.414	1.409 1.999 0.757 2.059	0.159 0.046 0.449 0.039	3 / 14 7 / 17 1 / 70	0/16 2/21		·	┼■			1	
J. Barbosa 4.324 W. Tang 3.423 E. S. Rosenberg 1.571	1.029 0.142 1.022	18.166 82.689 2.414	1.999 0.757 2.059	0.046 0.449 0.039	7/17 1/70	2/21					5		
W. Tang 3.423 E. S. Rosenberg 1.571 1.608 Random effect model	0.142 1.022	82.689 2.414	0.757 2.059	0.449 0.039	1/70							-	10.21
E. S. Rosenberg 1.571 1.608 Random effect model	1.022	2.414	2.059	0.039								22	22.68
1.608 Random effect model					52/271	0/80				-	_	-	8.79
Random effect model	0.548	4.719	0.864	0 387		27/22	:1			-			35.82
				0.007						÷.			
							,	.01	0.1		10	100	
Study name		Statistics for	each study			Events /	Total			isk difference and 96	×0		
Risk S	Standard	L	Lower Uppe	r									Relative
difference Z. Chen -0.226					p-Value	Group-A 2/31	Group-B 9 / 31	Ť	a		1	r	weight
Z Chen -0.226 P. Gaufret (B) 0.214	0.093		-0.407 -0.0		0.015	3/14	0/16						15.65 11.87
J. Barbosa 0.317	0.135	0.018	0.051 0.5		0.019	7/17	2/21						9.66
W. Tang 0.014	0.019	0.000	-0.023 0.0	52 0.746	0.456	1/70	0/80						32.79
E. S. Rosenberg 0.070	0.033	0.001	0.006 0.1	33 2.144	0.032	52/271	27/221						30.03
0.046	0.050	0.002	-0.051 0.1	44 0.933	0.351				1	-	, j		
								-1.00	-0.50	0.00	0.50	1.00	
Random effect model													
0.046	0.050	0.002	-0.051 0.1	44 0.933	0.351			l					

Group-A: Hydroxychloroquine

Group-B : Control

Figure 10. Forest plot for pooling risk ratios and risk differences regarding disease exacerbation in comparative randomized and non-randomized studies



Group-B : Control

Figure 11. Forest plot for pooling risk ratios and risk differences regarding disease exacerbation in only controlled randomized studies

Intubation

Meta-analysis of comparative randomized and non-randomized studies indicated that there were no significant differences between HCQ group and control group about odds of intubation during treatment (OR: 2.11, 95% CI, 0.31-14.03) (Fig. 12).

Odds Ratio

tudy name		Stati	stics for eac	h study		Events	/Total		Odds	ratio and 9	5% CI		
	Odds ratio	Lower limit	Upper limit	Z-Value	p-Value	Group-A	Group-B						Relative weight
J. Magagnoli	0.935	0.446	1.961	-0.177	0.860	12/90	25/177	1	1		1	1	58.48
J. Barbosa	6.650	1.158	38.195	2.124	0.034	7/17	2/21				_∎		41.52
	2.112	0.318	14.038	0.773	0.439				-				
								0.01	0.1	1	10	100	
	ect mode												

Figure 12. Forest plot for pooling odds ratios regarding intubation status

Adverse effects

The meta-analysis of comparative randomized and non-randomized studies showed that the odds of adverse effects occurrence in patients who received HCQ regimen was approximately 3.5 times higher than control group without HCQ regimen (OR: 3.55, 95% CI, 1.61-7.82) (Fig. 13). Likewise, doing meta-analysis only on controlled randomized studies indicated 4.5 times higher odds of experiencing adverse effects in patients who receive HCQ regimen in comparison to control group (OR: 4.53, 95% CI, 1.86-11.03) (Fig. 14). However, due to high relative weight of Tang *et al.* study, the sensitivity analysis by excluding this study resulted in no significant differences for odds of adverse effects between two groups (OR: 1.97, 95% CI, 0.44-8.77) (Supplementary Fig. 10).


• • •	
Odds	s Ratio

Study name		Stat	istics for eac	h study		Events	s / Total		Odds	s ratio and 95%	CI	
	Odds ratio	Lower limit	Upper limit	Z-Value	p-Value	Group-A	Group-B					Relative weight
Z. Chen	5.339	0.246	115.890	1.067	0.286	2/31	0/31					6.56
C. Jun	1.455	0.264	8.009	0.430	0.667	4 / 15	3/15		-		_	21.37
W. Tang	4.469	1.765	11.314	3.159	0.002	21/70	7/80					72.07
	3.558	1.617	7.827	3.154	0.002							
								0.01	0.1	1	10	100
Fixed effect	model							0.01	0.1	1	10	100
	$ity \cdot I^2 = C$	$0\%, T^2 =$	0.00. p-va	lue = 0.50	z-value =	3.15, df = 2	2		Favours A		Favours B	

Group-A : Hydroxychloroquine Group-B : Control

Figure 13. Forest plot for pooling odds ratios regarding adverse effects in comparative randomized and nonrandomized

Odds Ratio



Group-A: Hydroxychloroquine Group-B: Control

Figure 14. Forest plot for pooling odds ratios regarding adverse effects in only controlled randomized studies

Radiological improvement

A considerable Computed Tomography-Scan (CT-Scan) improvement was observed in HCQ group with odds ratio of 0.32 (95% CI, 0.11-0.98) (Fig. 15).

Odds Ratio

tudy name		Stati	stics for eac	h study		Events	s / Total		Odds	s ratio and 9	5% CI		
	Odds ratio	Lower limit	Upper limit	Z-Value	p-Value	Group-A	Group-B						Relativ weigt
Z. Chen	0.169	0.033	0.860	-2.142	0.032	2/31	9/31	Ĭ		<u> </u>	1	ľ	45.
C. Jun	0.571	0.130	2.503	-0.743	0.458	5/15	7/15		_				54.
	0.329	0.110	0.984	-1.989	0.047								
								0.01	0.1	1	10	100	
Fixed effec		F F 4 04 - 2	0.44			= -1.84, df							

Group-A: Hydroxychloroquine Group-B: Control

Figure 15. Forest plot for pooling odds ratios regarding radiological improvement

Meta-analysis of observational studies (Fig. 16)

We considered the treatment arms of the comparative studies as observational studies for this section. Hence, the meta-analysis of the other events rate showed the following results: 23% of patients suffered from known HCQ adverse effects (95% CI, 14%-36%); CT-Scan improvement has been observed in 16% of COVID-19 patients (95% CI, 2%-57%); 71% (95% CI, 58%-81%) of patients were discharged from the hospital or their nasopharyngeal culture resulted negative in RT-PCR evaluation, whereas 12% (95% CI, 2%-38%) of patients have been exacerbated, 7% (95% CI, 2%-17%) were admitted to the intensive care unit (ICU) and 23% (95% CI, 6%-57%) underwent intubation.

Group by Subgroup within study	Study name	Subgroup within study		Statis	tics for ea	ch study			Event rate and 95% CI
ubgroup within study			Event rate	Lower limit	Upper limit	Z-Value	p-Value	Total	
Adverse Effect	Z. Chen	Adverse Effect	0.065	0.016	0.224	-3.658	0.000	2/31	
Adverse Effect	C. Jun	Adverse Effect	0.267	0.104	0.533	-1.733	0.083	4/15	
Adverse Effect	W. Tang	Adverse Effect	0.300	0.204	0.417	-3.249	0.001	21/70	
Adverse Effect	J.E.Lee	Adverse Effect	0.259	0.129	0.453	-2.391	0.017	7/27	
Adverse Effect	0. 1. 100	Adverse Eneor	0.234	0.142	0.361	-3.774	0.000	1121	
CT-Scan Progression	Z Chen	CT-Scan Progression	0.065	0.016	0.224	-3.658	0.000	2/31	
CT-Scan Progression	C. Jun	CT-Scan Progression	0.333	0.146	0.594	-1.266	0.206	5/15	
CT-Scan Progression	C. Jun	C1-Scan Plogression	0.333	0.028	0.578	-1.643	0.100	5715	
D or NC*	1.84	D or NC*						70/97	
	J. Magagnoli		0.722	0.624	0.802	4.205	0.000		
D or NC*	Z Chen	D or NC*	0.806	0.631	0.910	3.139	0.002	25/31	
D or NC*	C. Jun	D or NC*	0.867	0.595	0.966	2.464	0.014	13/15	
D or NC*	P. Gautret (B)	D or NC*	0.571	0.316	0.794	0.533	0.594	8/14	
D or NC*	P. Gautret (A)	D or NC*	0.813	0.712	0.884	5.119	0.000	65/80	
D or NC*	J. M. Molina	D or NC*	0.200	0.050	0.541	-1.754	0.080	2/10	
D or NC*	W. Tang	D or NC*	0.857	0.754	0.921	5.246	0.000	60/70	
D or NC*	J. Mallat	D or NC*	0.478	0.288	0.675	-0.208	0.835	11/23	
D or NC*			0.710	0.582	0.812	3.099	0.002		
Exacerbation	J. Barbosa	Exacerbation	0.412	0.210	0.648	-0.724	0.469	7/17	
Exacerbation	Z Chen	Exacerbation	0.065	0.016	0.224	-3.658	0.000	2/31	
Exacerbation	P. Gautret (B)	Exacerbation	0.214	0.071	0.494	-1.995	0.046	3/14	
Exacerbation	W. Tang	Exacerbation	0.014	0.002	0.094	-4.204	0.000	1/70	
Exacerbation	J. E. Lee	Exacerbation	0.444	0.002	0.631	-0.576	0.565	12/27	
Exacerbation	E. S. Rosenberg	Exacerbation	0.192	0.149	0.243	-9.321	0.000	52/271	
Exacerbation	L. S. Rosenberg	LACEIDAUON	0.192	0.095	0.243	-9.321	0.000	32121	
	7.00	IOI Ladadaalaa						2/24	
CU admission	Z Chen	ICU admission	0.065	0.016	0.224	-3.658	0.000	2/31	
CU admission	P. Gautret (A)	ICU admission	0.038	0.012	0.110	-5.514	0.000	3/80	
CU admission	J. M. Molina	ICU admission	0.182	0.046	0.507	-1.924	0.054	2/11	
CU admission			0.071	0.028	0.170	-5.096	0.000		
ntubation	J. Magagnoli	Intubation	0.133	0.077	0.220	-6.036	0.000	12/90	
ntubation	J. Barbosa	Intubation	0.412	0.210	0.648	-0.724	0.469	7/17	
tubation			0.238	0.066	0.579	-1.538	0.124		
Adverse Effect Random effect model									-1.00 -0.50 0.00 0.50
Heterogeneity: I ² = 45.8	8%, τ² = 0.17, p	-value = 0.13, z-val	lue = -3	.77, df =	3				
CT-Progression						E	Exacerba	tion	
Random effect model						- F	Random	effect mode	lel
Heterogeneity: I2 = 78.7	$3\% t^2 = 1.54$ n	-value = 0.03 z-val	ue = -1	64 df =	1		leteroae	neity: 12 = 7	79.34%, r ² = 0.72, p-value = 0.00, z-value = -3.42, df = 5
iotorogeneity. 1 - 70.7	ova, i – 1.34, p		uo1.		1				
D or NC*							CU admi		
Random effect model								effect mode	
	0%, τ ² = 0.45, p	-value = 0.00, z-val	ue = 3.	09, df = 1	7	ŀ	leteroge	neity: $I^2 = 3$	36.92%, r ² = 0.28, p-value = 0.20, z-value = -5.09, df = 2
Heterogeneity: I ² = 74.8									
Intubation									

* D or NC: Discharge or Negative Culture

Figure 16. Forest plot for pooling events of observational studies

Discussion

More than three months after the closure of the Hubei region, there is still very little highquality data on every treatment's regimen, which raises questions about gaps in scientific works. In this context, one can only be surprised to see observational data without a control group covering a large number of patients when there is an essential need for comparative randomized data. In fact, Analysis of current data is difficult because at least 90% of spontaneous recovery are observed at the base. Thus, it takes well over 90% of recovery to consider that any treatment really brings something. The HCQ was no exception to this rule with a result greater than 90%. On the other hand, in a few percent, the disease becomes serious with Acute Respiratory Distress Syndrome (ARDS) and multi-organ failure. This is where we would like to know what the treatments bring. Concerning all of the limitations and analyze difficulties, we have conducted this systematic review and meta-analysis with great caution and sensitivity in performing analyzes in order to try for overcoming the current controversies regarding effectiveness of HCQ in the treatment of COVID-19, at least at the base.

To be honest, we know that all the studies taken into account should not be so if we wanted to respect the gold standard of performing a meta-analysis. However, few studies are currently available and the idea of this work is to maximize the use of everything that exists. Especially since we know, in principle, that observational studies give an overestimation of the value sought. Thus, whatever the result with the HCQ we can say that the result, by our approach, is also an overestimation of reality; which is very interesting in itself to get now.

Considering the matter, recent investigations indicated that a high concentration of cytokines in the plasma called cytokine storm would be related to severe COVID-19 patients. In this situation, medications transposition is a critical need to find effective anti-inflammatory agents to decrease the cytokines and pro-inflammatory factors production ³². In this regard, HCQ has been known as an effective anti-inflammatory agent for a long time (since the 1950s), especially in autoimmune disorders ³³. Besides, the outcome of a new experimental study conducted by Liu *et al.* has been mentioned in the title of their publication as follows: *"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro*". This also has been investigated and resulted same as the *in vitro* study of Yao *et al.* ³⁴.

In addition, Pagliano *et al.* in their letter to the editor of *Clinical Infectious Diseases (CID)* journal, have been recommended the use of HCQ as pre/post-exposure prophylaxis against SARS-CoV-2 infection for health care staffs exposed to the virus in contaminated environments ³⁵.

In contrast, Maurizio Guastalegname and Alfredo Vallone are claiming about the uselessness and even harmful effects of HCQ against COVID-19 in their letter to the editor in the above journal ⁶. They believe that, while the pathogenicity of the SARS-CoV-2 is still unknown, we should be cautious about the treatment decision, which has been proved through *in vitro* base studies in order to avoid dire paradoxical consequences like what has happened in treatment of *Chikungunya Virus* infection with chloroquine ³⁶. Moreover, Molina *et al.* have followed 11 patients with HCQ + azithromycin regimen and concluded no clinical benefit and reasonable anti-viral activity ¹⁹. In addition, the pre-print of a Quasi-Randomized Comparative Study conducted in Detroit, Michigan, has been indicated not only any clinical benefits for HCQ but even increased need for urgent respiratory support (p=0.013) ²¹.

Also, H.J. Kim *et al.* in their opinion publication *for the COVID-19 Global Rheumatology Alliance* pointed at the shortage of HCQ following a sudden high demand after Gautret and colleagues' publication on 20 March 2020¹⁷. They also referred to that HCQ is a crucial treatment choice for patients with systemic lupus erythematosus and rheumatoid arthritis disorders, who get into trouble in finding HCQ in this critical time ³⁷. Authors recommend that scientific communities have to be very cautious and do not rush in the decision when there is no ample evidence for the subject, especially in such critical situations, which can lead to irreparable consequences. In fact, even if the efficacy of HCQ is confirmed, the world will be facing a new issue for both COVID-19 and rheumatic disorders patients: "*Shortage of Hydroxychloroquine*".

More recently, the preprinted study of Magagnoli *et al.* ¹⁸ on 368 United States veterans reported not only any clinical benefits for HCQ/HCQ+AZM regimen in COVID-19 patients but even association between higher mortality rate and HCQ group (hazard ratio: 2.61, 95% CI, 1.10-6.17; P=0.03). Also, the target trial emulation conducted by Mahévas *et al.* ¹⁴, did not support the effectiveness of the HCQ regimen, which has performed on 181 patients with SARS-CoV-2 hypoxic pneumonia.

Observational Study of Geleris *et al.* ³⁰ in New York City on 1376 COVID-19 patients concluded that "*the study results should not be taken to rule out either benefit or harm of hydroxychloroquine treatment, given the observational design and the 95% confidence interval*". However, due to that investigators have combined the results of intubation and death together, we could not enter the results into meta-analysis. Another study conducted in New York State by Rosenberg *et al.* ²⁸ on "Association of Treatment With HCQ/AZM With In-Hospital Mortality in COVID-19 Patients" has also similarly concluded no association for lower in-hospital mortality for both medications.

In this case, we carried out the present systematic review in order to reach a clear result regarding taking or not-taking HCQ. In this study, meta-analysis revealed no significant differences between HCQ arm who received 400-600 mg HCQ daily regimen and standard treatment arm, which was the same for the HCQ+AZM regimen as well. Surprisingly, not only no clinical benefits were found regarding HCQ treatment with/without AZM for COVID-19 patients, but based on multiple sensitivity analysis the higher mortality rates were observed for both HCQ and HCQ+AZM regimen groups in comparison to control groups. For mortality, considering meta-regression analysis, age differences were significantly affected obtained risk ratios. In addition, more cases in the HCQ group presented the improvement in CT-Scan results in comparison to the control group. Moreover, the considerable higher frequency of known HCQ adverse effects such as diarrhea, vomiting, blurred vision, rash, headache, etc. was observed in HCQ groups.

It is remarkable that, Sarma *et al.* ⁸ conducted a meta-analysis on three studies and has been concluded the promising effects for HCQ clinical cure, which is inconsistent with our overall conclusion. Additionally, more recently, Million *et al.* ⁷ carried out "*a meta-analysis based on the first available reports*" released in *IHU Méditerranée Infection (COVID-IHU #10)*, in which they have claimed a promising trend toward the chloroquine derivatives benefits against COVID-19 and suggested it to prescribe as a grade *I* recommendation. Going deeper into the content, the study suffers from some flaws such as ignoring heterogeneity as well as the pattern of dispersion in the results, combining different outcomes in an unusual way, using only odds ratios, when the risk ratios are the priority and preferred in such analysis, talking about four RCTs, whereas some are non-randomized, etc. Also, concerning the importance of mortality,

Magagnoli *et al.* ¹⁸ findings, which go against the expected by authors, is ignored without any sensitivity analysis.

As a matter of fact, "statistics are only a tool for understanding and not an end in itself. If it is easy to say anything with statistics, it is also easy to say that you can make them say anything. However, using it well, with a strong consideration of the clinical sciences and an understanding of the possible sense of bias can go very far", Dr. Rauss says.

While our analysis did not indicate a considerable effectiveness for the HCQ/HCQ+AZM regimen, due to the small number of studies with a small sample size, it is too early to reach a reliable decision. In fact, the possible influence of biases on the results in analysis of such data is inevitable, but what is more important is to know in which direction, the biases can play the role on the results. Thus, as we know, observational studies give a vision that overestimates the real result. Under these conditions, when we incorporate such data, and the result is not good, it means that we have a minimized vision of the result. Hence, the question arises whether the result might be even worse than what is observed?! If yes, then it would be understood that "impact of this meta-analysis finings with strong consideration of the clinic and an understanding of the possible sense of bias is much greater than what is observed and presented"; Dr. Rauss says. Hence, it seems that we are very far from an effective treatment and the urgent need arises for comprehensive randomized controlled trials in order to investigate the efficacy and safety of HCQ consumption and other treatment regimen and approaches in COVID-19 patients. In point of fact, the studies to come should completely reverse what has already been done and just this point is already an important information because the probability is, in fact, extremely low.

In this regard, searching clinical trials registry databases such as WHO International Clinical Trials Registry Platform (ICTRP), Clinicaltrials.gov, Center Watch, Chinese Clinical Trials Registry, International Standard Randomised Controlled Trial Number (ISRCTN), EU Clinical Trials Register, OpenTrials and Iranian Registry of Clinical Trials, resulted in hundreds registered trials on the subject of efficacy, safety and prophylaxis potency of HCQ in COVID-19 patients. Hence, in the near future, the results of these trials will help the medical communities to reach a general opinion regarding the utilization of HCQ as a pre/post-exposure as well as a treatment option for patients infected with SARS-CoV-2.

To our knowledge, this is the most updated systematic review that carried out a meta-analysis for investigating the role of HCQ with/without AZM in COVID-19 patients. However, after releasing outcomes of underway clinical trials, especially "*Solidarity*" clinical trial for COVID-19 treatment by WHO, an updated systematic review and meta-analysis on this subject could be more conclusive and reliable.

It is worth noting that the current meta-analysis includes the following limitations: 1) due to that most of the studies were non-randomized and results were not homogenous, selection bias was unavoidable; 2) various treatment plan regarding medication dosage and treatment duration; 3) insufficient moderator variables distribution by group such as sex, underlying disease, etc.; and 4) inclusion of studies with small sample size, which leads to type *II* statistical errors. To overcome the limitations and bias, results of the study should be confirmed by robustly randomized studies.

Conclusion

This systematic review and meta-analysis indicated no clinical benefits regarding hydroxychloroquine treatment with/without azithromycin for COVID-19 patients. Surprisingly, according to multiple sensitivity analysis the higher mortality rates were observed for both HCQ and HCQ+AZM regimen groups, especially in the latter, which was affected by age factor. Also, frequency of known HCQ adverse effects was higher in this regimen group in comparison to the controls. However, due to that most of the studies were non-randomized and results were not homogenous, selection bias was unavoidable, further large clinical trials following comprehensive meta-analysis should be taken into account in order to achieve more reliable findings.

Conflict of interests

The authors declare that they have no conflict of interests.

Acknowledgments:

We would like to express our deepest appreciation to Dr. Alain Rauss, who extended a great amount of assistance in regards to clinical and statistical contents of the study with his insightful advice and comments. Our gratitude should also go to the Student Research Committee of Mazandaran University of Medical Sciences for supporting this student research proposal with the code 7586.

References:

- 1. Organization WH. Coronavirus disease (COVID-2019) situation reports. In: Geneva: WHO; 2020.
- 2. Organization WH. Coronavirus disease (COVID-19) advice for the public. 2020.
- 3. Pourdowlat G, Panahi P, Pooransari P, Ghorbani F. Prophylactic Recommendation for Healthcare Workers in COVID-19 Pandemic. *J Advanced Journal of Emergency Medicine*. 2020.
- 4. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. *Int J Antimicrob Agents*. 2020:105932.
- 5. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. *The Journal of antimicrobial chemotherapy*. 2020.
- 6. Guastalegname M, Vallone A. Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment? *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2020.
- 7. Million M, Gautret Ph, Raoult D. The efficacy of Chloroquine derivatives in COVID-19: a meta-analysis based on the first available reports2020, IHU Méditerranée Infection.
- 8. Sarma P, Kaur H, Kumar H, et al. Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis. *J Med Virol.* 2020;n/a(n/a).
- 9. McGuinness LA. robvis: An R package and web application for visualising risk-of-bias assessments. 2019.
- 10. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of interventions version 6.0.* 2nd Edition ed: John Wiley & Sons; 2019.
- 11. Bown MJ, Sutton AJ. Quality Control in Systematic Reviews and Meta-analyses. *European Journal of Vascular and Endovascular Surgery*. 2010;40(5):669-677.
- 12. CHEN Jun LD, LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING Yun,HUANG Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). 2020;49(1):0-0.
- 13. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. 2020:2020.2003.2022.20040758.
- 14. Mahevas M, Tran V-T, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. 2020:2020.2004.2010.20060699.
- 15. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. 2020:2020.2004.2010.20060558.
- 16. Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. *IHU Méditerranée Infection*. 2020;27(1).
- 17. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020:105949.
- 18. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. 2020:2020.2004.2016.20065920.
- 19. Molina JM, Delaugerre C, Goff JL, et al. No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection. *Médecine et Maladies Infectieuses*. 2020.
- 20. Chorin E, Dai M, Shulman E, et al. The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin. 2020:2020.2004.2002.20047050.
- 21. Barbosa J, Kaitis D, Freedman R, Le K, Lin X. Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19 : a quasi-randomized comparative study. *Bibliovid.* 2020.
- 22. al. MMe. Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France. *Bibliovid.* 2020.
- 23. Yu B, Wang DW, Li C. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. 2020;2020.2004.2027.20073379.
- 24. Membrillo de Novales FJ, Ramírez-Olivencia G, Estébanez M, et al. Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study. *Preprints.* 2020.

- 25. Mallat J, Hamed F, Balkis M, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. 2020:2020.2004.2027.20082180.
- 26. Lee JE, Lee SO, Heo J, et al. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of coronavirus disease 2019 with mild to moderate severity. *PREPRINT available at Research Square*. 2020;(Version 1).
- 27. Barbosa Esper R, Souza da Silva R, Costa Oikawa FT, et al. Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine. *Dropbox.* 2020.
- 28. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA*. 2020.
- 29. Saleh M, Gabriels J, Chang D, et al. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. *Circulation: Arrhythmia and Electrophysiology.* 2020.
- 30. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *The New England Journal of Medicine*. 2020.
- 31. Ramireddy A, Chugh HS, Reinier K, et al. Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring. 2020:2020.2004.2022.20075671.
- 32. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. *Int J Antimicrob Agents*. 2007;30(4):297-308.
- 33. Detert J, Klaus P, Listing J, et al. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial. *Trials.* 2014;15:412.
- 34. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* 2020.
- 35. Pagliano P, Piazza O, De Caro F, Ascione T, Filippelli A. Is Hydroxychloroquine a possible post-exposure prophylaxis drug to limit the transmission to health care workers exposed to COVID19? *Clin Infect Dis.* 2020.
- 36. Roques P, Thiberville SD, Dupuis-Maguiraga L, et al. Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection. *Viruses*. 2018;10(5).
- 37. Kim AHJ, Sparks JA, Liew JW, et al. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. *Annals of internal medicine.* 2020.